Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | TKT | P29401 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3938309 | 0.79 | CCR1 (0.48) | ALDH1A1KDM4E | |
| SCHEMBL14496830 | 0.79 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL10271989 | 0.78 | PARP1 (0.34) | ALDH1A1NOS3NOS2PARP1HTT | |
| SCHEMBL10730430 | 0.78 | NOS3 (0.46) | NOS3NOS2PARP1TKTKDM4E | |
| SCHEMBL11814271 | 0.76 | MEN1 (0.35) | ALDH1A1NOS3NOS2PARP1TKT | |
| SCHEMBL9753081 | 0.76 | NOS2 (0.43) | NOS3NOS2PARP1TKTLMNA | |
| SCHEMBL24590757 | 0.74 | MBOAT4 (0.40) | ALDH1A1PARP1LMNAKDM4ECYP1A2 | |
| SCHEMBL10272814 | 0.74 | NOS3 (0.33) | ALDH1A1NOS3NOS2PARP1HTT | |
| SCHEMBL112688 | 0.74 | NOS3 (0.38) | ALDH1A1NOS3NOS2PARP1TKT | |
| SCHEMBL9127909 | 0.74 | NOS3 (0.33) | NOS3NOS2PARP1TKT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022002245-A1 | ATR INHIBITORS AND USES THEREOF | SHANGHAI ANTENGENE CORPORATION LIMITED (CN) | 2022-01-06 | — | — | WO | disclosed |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118740-A1 | AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN1, GRIN2B, GRIN3A | ALDH1A1 721/4885NOS3 672/4885NOS2 592/4885 |
| US-11345712-B2 | Protein-targeting compounds and pharmaceutical compositions thereof, and their therapeutic applications | HSP90B1, EIF4EBP1, SERPINA6 | ALDH1A1 4668/4885NOS3 4368/4885NOS2 4234/4885 |
| US-20200369679-A1 | PROTEIN-TARGETING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HSP90B1, EIF4EBP1, SERPINA6 | ALDH1A1 4668/4885NOS3 4368/4885NOS2 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.